Behçet- und Cogan-Syndrom

Zusammenfassung

Das Behçet- und das Cogan-Syndrom bilden zusammen die Gruppe der Vaskulitiden der variablen Gefäße nach der Chapel-Hill Nomenklatur. Sie können Arterien und Venen jeder Größe betreffen. Wie die Bezeichnung „Syndrom“ bei beiden Krankheitsbildern bereits widerspiegelt, können beide individuell sehr unterschiedliche Symptome bieten. Beide zählen formal zu den seltenen Erkrankungen, wobei das Cogan-Syndrom mit der Beschreibung von lediglich einigen hundert Fällen weltweit deutlich seltener als das Behςet-Syndrom ist. Für letzteres gibt es Diagnose- und Klassifikationskriterien, und auch europäische (EULAR, European Alliance of Associations for Rheumatology) Therapieempfehlungen. Symptomatologie, Diagnostik und Therapie, aber auch einige Überlegungen zur Pathogenese dieser beiden Vaskulitiden werden im Folgenden beleuchtet.

Abstract

Behçet’s syndrome and Cogan’s syndrome constitute the group of variable vessel vasculitides in the Chapel-Hill Nomenclature. They involve arteries and veins of all sizes. As reflected in the name “syndrome”, both diseases can manifest with different individual symptoms. Both formally are rare diseases, but the Cogan syndrome is much rarer than Behçet`s. For the latter, there are diagnosis and classification criteria as well as European (EULAR, European Alliance of Associations for Rheumatology) treatment recommendations. The symptomatology, diagnostic measures and treatment as well as some considerations about pathogenesis will be discussed in this article.

Schlüsselwörter

Behçet - Cogan - Pathogenese - Diagnose - Therapie

Key words

Behçet - Cogan - pathogenesis - diagnosis - treatmentonline publiziert 2022

Publikationsverlauf

Artikel online veröffentlicht:
02. November 2022

• Literatur

• 1 Behcet H. Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien. Dermatol Wschr 1937; 105: 1152-1157
• 2 Adamantiades B. A case of relapsing iritis with hypopion (in Greek). Archia Iatrikis Etairas (Proceedings of hte Medical Society of Athens). 1930 586-539
• 3 Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 2013; 17: 603-606
• 4 Norton EW, Cogan DG. Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms; a long-term follow-up. AMA Arch Ophthalmol 1959; 61: 695-697
• 5 Cogan DG. Nonsyphilitic interstitial keratitis with vestibuloauditory symptoms; report of four additional cases. Arch Ophthal 1949; 42: 42-49
• 6 Mahr A, Maldini C. [Epidemiology of Behcet’s disease]. Rev Med Interne 2014; 35: 81-89
• 7 Altenburg A, Mahr A, Maldini C. et al. [Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany : Current data]. Ophthalmologe 2012; 109: 531-541
• 8 Durtette C, Hachulla E, Resche-Rigon M. et al. Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review. Autoimmun Rev 2017; 16: 1219-1223
• 9 Gluth MB, Baratz KH, Matteson EL. et al. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 2006; 81: 483-488
• 10 McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 3: e297
• 11 Deng Y, Zhu W, Zhou X. Immune Regulatory Genes Are Major Genetic Factors to Behcet Disease: Systematic Review. The open rheumatology journal 2018; 12: 70-85
• 12 Tong B, Liu X, Xiao J. et al. Immunopathogenesis of Behcet’s Disease. Frontiers in immunology 2019; 10: 665
• 13 McGonagle D, Aydin SZ, Gul A. et al. Reply to: Behcet’s disease: an MHC-I-opathy?. Clin Exp Rheumatol 2017; 35: 6
• 14 Gul A, Ohno S. HLA-B*51 and Behcet Disease. Ocul Immunol Inflamm 2012; 20: 37-43
• 15 Bhandari GS, Duggal L, Jain N. et al. Cogan syndrome: An autoimmune eye and ear disease with systemic manifestations. Natl Med J India 2019; 32: 349-351
• 16 Kamakura T, Lee DJ, Herrmann BS. et al. Histopathology of the Human Inner Ear in the Cogan Syndrome with Cochlear Implantation. Audiol Neurootol 2017; 22: 116-123
• 17 Kessel A, Vadasz Z, Toubi E. Cogan syndrome – pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2014; 13: 351-354
• 18 Kotter I. Behcet’s syndrome: Current diagnostics and treatment. Z Rheumatol 2020; 79: 873-882
• 19 Kotter I, Lotscher F. Behcet’s Syndrome Apart From the Triple Symptom Complex: Vascular, Neurologic, Gastrointestinal, and Musculoskeletal Manifestations. A Mini Review. Front Med (Lausanne) 2021; 8: 639758
• 20 Yazici H, Seyahi E, Hatemi G. et al. Behcet syndrome: a contemporary view. Nat Rev Rheumatol 2018; 14: 107-119
• 21 Seyahi E. Phenotypes in Behcet’s syndrome. Intern Emerg Med 2019; 14: 677-689
• 22 Zou J, Luo JF, Shen Y. et al. Cluster analysis of phenotypes of patients with Behcet’s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther 2021; 23: 45
• 23 [Anonym] Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 1990; 335: 1078-1080
• 24 International Team for the Revision of the International Criteria for Behcet’s D. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338-347
• 25 Antonios N, Silliman S. Cogan syndrome: an analysis of reported neurological manifestations. Neurologist 2012; 18: 55-63
• 26 Casselman JW, Majoor MH, Albers FW. MR of the inner ear in patients with Cogan syndrome. AJNR Am J Neuroradiol 1994; 15: 131-138
• 27 Hatemi G, Christensen R, Bang D. et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis 2018; 808-818
• 28 Kural-Seyahi E, Fresko I, Seyahi N. et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76
• 29 Hatemi G, Mahr A, Ishigatsubo Y. et al. Trial of Apremilast for Oral Ulcers in Behcet’s Syndrome. N Engl J Med 2019; 381: 1918-1928
• 30 Merrill PT, Vitale A, Zierhut M. et al. Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials. Ocul Immunol Inflamm 2020; 1-7
• 31 Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the Treatment of Behcet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocul Immunol Inflamm 2018; 26: 1005-1014
• 32 Padoan R, Cazzador D, Pendolino AL. et al. Cogan’s syndrome: new therapeutic approaches in the biological era. Expert Opin Biol Ther 2019; 19: 781-788
• 33 Kougkas N, Bertsias G, Stratoudaki R. et al. Successful treatment of Cogan’s syndrome with tocilizumab. Scand J Rheumatol 2021; 50: 330-331
• 34 Venhoff N, Thiel J, Schramm MA. et al. Case Report: Effective and Safe Treatment With Certolizumab Pegol in Pregnant Patients With Cogan’s Syndrome: A Report of Three Pregnancies in Two Patients. Front Immunol 2020; 11: 616992
• 35 Bovo R, Ciorba A, Trevisi P. et al. Cochlear implant in Cogan syndrome. Acta Otolaryngol 2011; 131: 494-497
• 36 D’Aguanno V, Ralli M, de Vincentiis M. et al. Optimal management of Cogan’s syndrome: a multidisciplinary approach. J Multidiscip Healthc 2018; 11: 1-11